CardiologyNowNews.org CardiologyNowNews.org
Font ResizerAa
  • Home
    • About
      • Message from the Editor-in-Chief
      • Mission Statement
      • Editorial Board
  • News
  • Topics
    • Acute Coronary Syndrome
    • Arrhythmia and Electrophysiology
    • Cardiovascular Imaging
    • Cardiovascular Intervention
    • Cardiovascular Prevention
    • Cerebrovascular Disease
    • Heart Failure
    • Peripheral Vascular Disease
    • Structural Heart Disease
    • Valvular Heart Disease
  • Educational Resources
    • WikiDoc
    • BAIM Grand Rounds
    • Clinical Trial Results
  • ACC
    • ACC 2017
    • ACC 2018
    • ACC 2019
    • ACC 2020
    • ACC 2021
    • ACC 2022
    • ACC 2023
    • ACC 2024
    • ACC 2025
    • ACC 2026
  • AHA
    • AHA 2017
    • AHA 2019
    • AHA 2021
    • AHA 2022
    • AHA 2023
    • AHA 2024
    • AHA 2025
    • AHA 2026
  • ESC
    • ESC 2017
    • ESC 2018
    • ESC 2019
    • ESC 2021
    • ESC 2022
    • ESC 2023
    • ESC 2024
    • ESC 2025
  • SCAI
    • SCAI 2017
    • SCAI 2018
  • Videos
CardiologyNowNews.org CardiologyNowNews.org
Font ResizerAa
Search
  • Home
    • About
  • News
  • Topics
    • Acute Coronary Syndrome
    • Arrhythmia and Electrophysiology
    • Cardiovascular Imaging
    • Cardiovascular Intervention
    • Cardiovascular Prevention
    • Cerebrovascular Disease
    • Heart Failure
    • Peripheral Vascular Disease
    • Structural Heart Disease
    • Valvular Heart Disease
  • Educational Resources
    • WikiDoc
    • BAIM Grand Rounds
    • Clinical Trial Results
  • ACC
    • ACC 2017
    • ACC 2018
    • ACC 2019
    • ACC 2020
    • ACC 2021
    • ACC 2022
    • ACC 2023
    • ACC 2024
    • ACC 2025
    • ACC 2026
  • AHA
    • AHA 2017
    • AHA 2019
    • AHA 2021
    • AHA 2022
    • AHA 2023
    • AHA 2024
    • AHA 2025
    • AHA 2026
  • ESC
    • ESC 2017
    • ESC 2018
    • ESC 2019
    • ESC 2021
    • ESC 2022
    • ESC 2023
    • ESC 2024
    • ESC 2025
  • SCAI
    • SCAI 2017
    • SCAI 2018
  • Videos
Follow US
AHA 2026News

FB7023: Lp(a) and LDL-C Reduction After Dual-Targeting siRNA in First-in-Human Study

Basir Gill
Share
6 Min Read
  • FB7023 (Frontier Biotechnologies) is an investigational small interfering RNA (siRNA) that targets both PCSK9 and LPA, designed to lower LDL-C and Lp(a) with one molecule.
  • Volunteers with LDL-C of at least 100 mg/dL and Lp(a) of at least 30 mg/dL were randomized to FB7023 300 mg or 600 mg, placebo, or open-label inclisiran at weeks 0 and 12.
  • At week 8, LDL-C fell by a mean of 34.9% and 38.5% with the two FB7023 doses, compared with 2.9% with placebo and 40.6% with inclisiran, and Lp(a) fell 96.5% and 99.2%, compared with 5.7% and 25.6%, respectively.
  • Safety and tolerability were the primary objective, and the investigators describe FB7023 as safe and well tolerated.

Lp(a) fell by a mean of 96.5% with FB7023 300 mg and 99.2% with the 600-mg dose at week 8 in interim results from a first-in-human study of the investigational siRNA. LDL-C fell by a mean of 34.9% and 38.5% with the two doses in the study, which enrolled volunteers with hyperlipidemia and elevated Lp(a). Michael Wang, PhD, presented the results at the American Heart Association (AHA) Scientific Sessions on November 8, 2026.

FB7023 is an N-acetylgalactosamine (GalNAc)-conjugated siRNA developed by Frontier Biotechnologies (Nanjing, China). It is designed to silence two genes with one molecule: PCSK9, the target of inclisiran, and LPA, which encodes apolipoprotein(a). Inclisiran is an approved siRNA that lowers LDL-C and is given at the start of treatment, at 3 months, and then every 6 months. Several siRNAs that silence LPA alone, including olpasiran, have been tested in clinical trials to lower Lp(a).

The study (ChiCTR2600129275) was a multi-arm, randomized, parallel, placebo-controlled trial. The registry entry describes the participants as healthy adults aged 18 to 55 years with elevated LDL-C and Lp(a). Entry required LDL-C of at least 100 mg/dL (2.59 mmol/L), Lp(a) of at least 30 mg/dL, and triglycerides below 400 mg/dL. People taking lipid-lowering therapy and those with cardiovascular disease, hypertension, or diabetes were excluded. Participants received FB7023 300 mg, FB7023 600 mg, placebo, or inclisiran at weeks 0 and 12. FB7023 and placebo were given double-blind, and inclisiran was given open label. Each FB7023 dose level began with a small sentinel cohort, and each later cohort was dosed only after a safety review of the cohorts before it. Follow-up is planned through week 24 and can be extended to week 36.

The primary objective was safety and tolerability. Secondary objectives were changes in LDL-C, total cholesterol, HDL-C, triglycerides, PCSK9, and Lp(a). The investigator-initiated study was conducted at Zhejiang Xiaoshan Hospital in China and funded by Frontier Biotechnologies, according to the registry entry.

The week-8 results, measured before the second dose, come from 14 participants. LDL-C fell by a mean of 34.9% with FB7023 300 mg (n=3) and 38.5% with FB7023 600 mg (n=2), compared with 2.9% with placebo (n=5) and 40.6% with inclisiran (n=4). Lp(a) fell 96.5% and 99.2% with the two FB7023 doses, compared with 5.7% with placebo and 25.6% with inclisiran.

The authors reported that FB7023 600 mg lowered LDL-C and PCSK9 to an extent comparable to an equimolar 300-mg dose of inclisiran. The investigators remained confident of the safety and tolerability measures.

They also reported a study in rhesus monkeys with spontaneous hyperlipidemia and elevated Lp(a). Single subcutaneous doses of FB7023 at 6 and 12 mg/kg were compared with inclisiran and olpasiran, each at 6 mg/kg, and the results showed LDL-C lowering comparable to inclisiran and Lp(a) lowering comparable to olpasiran.. The authors wrote that FB7023 has potential for dosing every 3 to 6 months.

The week 8 results are interim and cover 14 of 27 participants, and two of the 14 received FB7023 600 mg. Inclisiran was given open label, while the FB7023 and placebo arms were blinded. Because people taking lipid-lowering therapy were excluded, the LDL-C and Lp(a) reductions were measured without background lipid-lowering therapy.

Inclisiran lowered Lp(a) by 25.6% in this study. In a phase 1 dose-escalation trial of olpasiran, which targets LPA alone, single doses of 9 mg or higher reduced Lp(a) by 71% to 97% (Koren et al., Nature Medicine, 2022). The reductions lasted for several months. For FB7023, how long the reductions last beyond week 8 remains unknown. Follow-up planned through week 24, and possibly week 36, may show whether the effects persist and how the safety profile holds up after the second dose.

TAGGED:AHA 2026FeaturedNews
Share This Article
Copy Link Print
CardiologyNowNews.org CardiologyNowNews.org
Copyright - CardiologyNowNews
  • Contact Us
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?